Open Access

American Association for the Advancement of Science (AAAS)

Science advances

, volume 6 , issue 23

Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer

P.R Sarode ¹

Xiang Zheng ¹

Georgia A. Giotopoulou ²

Andreas Weigert ³

Carsten Kuenne ¹

Stefan Günther ¹

Aleksandra Friedrich ¹

Stefan Gattenlöhner ⁴

Thorsten Stiewe ⁵

Bernhard Brüne ^{3, 6}

Friedrich Grimminger ⁷

Georgios T Stathopoulos ²

Soni S. Pullamsetti ^{1, 7}

WERNER SEEGER ^{1, 7, 8}

Rajkumar Savai ^{1, 6, 7, 8}

Hide authors affiliations Show authors affiliations: 8 affiliations

Max Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Member of the Cardio-Pulmonary Institute (CPI), Bad Nauheim 61231, Germany.

Max Planck Institute for Heart and Lung Research

Cardio-Pulmonary Institute

German Center for Lung Research

Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, 26504, Greece and Lung Carcinogenesis Laboratory, Comprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich 81377, Germany.

Ludwig Maximilian University of Munich

German Center for Lung Research

Institute of Biochemistry I, Faculty of Medicine, Goethe University Frankfurt, Frankfurt 60323, Germany. |

⁴

Department of Pathology, Member of the DZL, Justus Liebig University, Giessen 35390, Germany. |

⁵

Institute of Molecular Oncology, Philipps-University Marburg, Member of the DZL, Marburg 35043, Germany. |

⁶

Frankfurt Cancer Institute (FCI), Goethe University, 60596 Frankfurt am Main, Germany.

Goethe University Frankfurt

Frankfurt Cancer Institute

⁷

Department of Internal Medicine, Member of the DZL, Member of CPI, Justus Liebig University, 35392 Giessen, Germany. |

⁸

Institute for Lung Health (ILH), Justus Liebig University, 35392 Giessen, Germany. |

Publication type: Journal Article

Publication date: 2020-06-05

American Association for the Advancement of Science (AAAS)

Science advances

scimago Q1

wos Q1

SJR: 4.324

CiteScore: 19.6

Impact factor: 12.5

ISSN: 23752548

DOI: 10.1126/sciadv.aaz6105

Copy DOI

PubMed ID: 32548260

Multidisciplinary

Abstract

Targeting β-catenin–dependent gene regulation in macrophages may offer a new immunotherapeutic option in lung cancer.

Found

Top-30

Journals

	2 4 6 8 10 12
Frontiers in Immunology	Frontiers in Immunology, 12, 7.5% Frontiers in Immunology 12 publications, 7.5%
Frontiers in Oncology	Frontiers in Oncology, 6, 3.75% Frontiers in Oncology 6 publications, 3.75%
Nature Communications	Nature Communications, 5, 3.13% Nature Communications 5 publications, 3.13%
Cells	Cells, 5, 3.13% Cells 5 publications, 3.13%
Scientific Reports	Scientific Reports, 4, 2.5% Scientific Reports 4 publications, 2.5%
Experimental and Molecular Medicine	Experimental and Molecular Medicine, 3, 1.88% Experimental and Molecular Medicine 3 publications, 1.88%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 3, 1.88% International Journal of Molecular Sciences 3 publications, 1.88%
Cell Death and Disease	Cell Death and Disease, 3, 1.88% Cell Death and Disease 3 publications, 1.88%
Journal of Cancer Research and Clinical Oncology	Journal of Cancer Research and Clinical Oncology, 3, 1.88% Journal of Cancer Research and Clinical Oncology 3 publications, 1.88%
JCI insight	JCI insight, 3, 1.88% JCI insight 3 publications, 1.88%
Journal of Ethnopharmacology	Journal of Ethnopharmacology, 3, 1.88% Journal of Ethnopharmacology 3 publications, 1.88%
bioRxiv	bioRxiv, 3, 1.88% bioRxiv 3 publications, 1.88%
Cancers	Cancers, 2, 1.25% Cancers 2 publications, 1.25%
Frontiers in Pharmacology	Frontiers in Pharmacology, 2, 1.25% Frontiers in Pharmacology 2 publications, 1.25%
Clinical and Experimental Medicine	Clinical and Experimental Medicine, 2, 1.25% Clinical and Experimental Medicine 2 publications, 1.25%
International Immunopharmacology	International Immunopharmacology, 2, 1.25% International Immunopharmacology 2 publications, 1.25%
Biochemical Pharmacology	Biochemical Pharmacology, 2, 1.25% Biochemical Pharmacology 2 publications, 1.25%
Biomaterials	Biomaterials, 2, 1.25% Biomaterials 2 publications, 1.25%
Advanced Science	Advanced Science, 2, 1.25% Advanced Science 2 publications, 1.25%
Molecular Carcinogenesis	Molecular Carcinogenesis, 2, 1.25% Molecular Carcinogenesis 2 publications, 1.25%
International Reviews of Immunology	International Reviews of Immunology, 2, 1.25% International Reviews of Immunology 2 publications, 1.25%
Evidence-based Complementary and Alternative Medicine	Evidence-based Complementary and Alternative Medicine, 2, 1.25% Evidence-based Complementary and Alternative Medicine 2 publications, 1.25%
Cancer Research	Cancer Research, 2, 1.25% Cancer Research 2 publications, 1.25%
Circulation Research	Circulation Research, 2, 1.25% Circulation Research 2 publications, 1.25%
Cancer immunology research	Cancer immunology research, 2, 1.25% Cancer immunology research 2 publications, 1.25%
Journal of the American Heart Association	Journal of the American Heart Association, 2, 1.25% Journal of the American Heart Association 2 publications, 1.25%
npj Precision Oncology	npj Precision Oncology, 2, 1.25% npj Precision Oncology 2 publications, 1.25%
Molecular Medicine Reports	Molecular Medicine Reports, 1, 0.63% Molecular Medicine Reports 1 publication, 0.63%
Chinese Medical Journal	Chinese Medical Journal, 1, 0.63% Chinese Medical Journal 1 publication, 0.63%
	2 4 6 8 10 12

Publishers

	5 10 15 20 25 30 35 40
Springer Nature	Springer Nature, 36, 22.5% Springer Nature 36 publications, 22.5%
Elsevier	Elsevier, 31, 19.38% Elsevier 31 publications, 19.38%
Frontiers Media S.A.	Frontiers Media S.A., 21, 13.13% Frontiers Media S.A. 21 publications, 13.13%
Wiley	Wiley, 16, 10% Wiley 16 publications, 10%
MDPI	MDPI, 13, 8.13% MDPI 13 publications, 8.13%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 8, 5% Cold Spring Harbor Laboratory 8 publications, 5%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 5, 3.13% Ovid Technologies (Wolters Kluwer Health) 5 publications, 3.13%
Hindawi Limited	Hindawi Limited, 4, 2.5% Hindawi Limited 4 publications, 2.5%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 4, 2.5% American Association for Cancer Research (AACR) 4 publications, 2.5%
American Society for Clinical Investigation	American Society for Clinical Investigation, 3, 1.88% American Society for Clinical Investigation 3 publications, 1.88%
Spandidos Publications	Spandidos Publications, 2, 1.25% Spandidos Publications 2 publications, 1.25%
Taylor & Francis	Taylor & Francis, 2, 1.25% Taylor & Francis 2 publications, 1.25%
Annual Reviews	Annual Reviews, 1, 0.63% Annual Reviews 1 publication, 0.63%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 1, 0.63% Public Library of Science (PLoS) 1 publication, 0.63%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 1, 0.63% Royal Society of Chemistry (RSC) 1 publication, 0.63%
BMJ	BMJ, 1, 0.63% BMJ 1 publication, 0.63%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 1, 0.63% American Association for the Advancement of Science (AAAS) 1 publication, 0.63%
eLife Sciences Publications	eLife Sciences Publications, 1, 0.63% eLife Sciences Publications 1 publication, 0.63%
Pharmaceutical Society of Korea	Pharmaceutical Society of Korea, 1, 0.63% Pharmaceutical Society of Korea 1 publication, 0.63%
European Molecular Biology Organization	European Molecular Biology Organization, 1, 0.63% European Molecular Biology Organization 1 publication, 0.63%
Proceedings of the National Academy of Sciences (PNAS)	Proceedings of the National Academy of Sciences (PNAS), 1, 0.63% Proceedings of the National Academy of Sciences (PNAS) 1 publication, 0.63%
Baishideng Publishing Group	Baishideng Publishing Group, 1, 0.63% Baishideng Publishing Group 1 publication, 0.63%
	5 10 15 20 25 30 35 40

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

PDF

Metrics

160

Cite this

GOST |

Cite this

GOST Copy

Sarode P. et al. Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer // Science advances. 2020. Vol. 6. No. 23.

GOST all authors (up to 50) Copy

Sarode P., Zheng X., Giotopoulou G. A., Weigert A., Kuenne C., Günther S., Friedrich A., Gattenlöhner S., Stiewe T., Brüne B., Grimminger F., Stathopoulos G. T., Pullamsetti S. S., SEEGER W., Savai R. Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer // Science advances. 2020. Vol. 6. No. 23.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1126/sciadv.aaz6105

UR - https://doi.org/10.1126/sciadv.aaz6105

TI - Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer

T2 - Science advances

AU - Sarode, P.R

AU - Zheng, Xiang

AU - Giotopoulou, Georgia A.

AU - Weigert, Andreas

AU - Kuenne, Carsten

AU - Günther, Stefan

AU - Friedrich, Aleksandra

AU - Gattenlöhner, Stefan

AU - Stiewe, Thorsten

AU - Brüne, Bernhard

AU - Grimminger, Friedrich

AU - Stathopoulos, Georgios T

AU - Pullamsetti, Soni S.

AU - SEEGER, WERNER

AU - Savai, Rajkumar

PY - 2020

DA - 2020/06/05

PB - American Association for the Advancement of Science (AAAS)

IS - 23

VL - 6

PMID - 32548260

SN - 2375-2548

ER -

BibTex

Cite this

BibTex (up to 50 authors) Copy

@article{2020_Sarode,

author = {P.R Sarode and Xiang Zheng and Georgia A. Giotopoulou and Andreas Weigert and Carsten Kuenne and Stefan Günther and Aleksandra Friedrich and Stefan Gattenlöhner and Thorsten Stiewe and Bernhard Brüne and Friedrich Grimminger and Georgios T Stathopoulos and Soni S. Pullamsetti and WERNER SEEGER and Rajkumar Savai},

title = {Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer},

journal = {Science advances},

year = {2020},

volume = {6},

publisher = {American Association for the Advancement of Science (AAAS)},

month = {jun},

url = {https://doi.org/10.1126/sciadv.aaz6105},

number = {23},

doi = {10.1126/sciadv.aaz6105}

}

Publisher

American Association for the Advancement of Science (AAAS)

Journal

Science advances

scimago Q1

wos Q1

SJR

4.324

CiteScore

19.6

Impact factor

12.5

ISSN

23752548 (Electronic)